Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Cyclophosphamide/doxorubicin/trastuzumab

Cyclophosphamide/doxorubicin/trastuzumab Reactions 1704, p124 - 2 Jun 2018 Cyclophosphamide/doxorubicin/ trastuzumab Irreversible left atrium dilatation, left ventricular dysfunction and atrial fibrillation with rapid ventricular response: case report A woman [exact age at the time of reaction onset not clearly stated] developed irreversible left atrium dilatation, atrial fibrillation with rapid ventricular response and left ventricular dysfunction following treatment with trastuzumab, cyclophosphamide and doxorubicin [dosages and routes not stated; not all durations of treatments to reactions onsets and outcomes stated]. The woman was diagnosed with stage IV invasive ductal left breast cancer in 2002 (at the age of 52 years) with bone metastases. Following left-modified radical mastectomy, she received treatment with six cycles of doxorubicin followed by adjuvant CMF regimen that consisted cyclophosphamide, concurrently with methotrexate and fluorouracil. In November 2008, due to disease progression, she received treatment with trastuzumab plus docetaxel combination therapy. No heart disease was observed at baseline. However, after 22 months of trastuzumab initiation, the left atrial volume index (LAVI) was found to be increased, but the left ventricular function was preserved. She presented with the symptoms of fatigue, palpitation and exertional dyspnoea after six months. Electrocardiography findings led to the diagnosis of atrial fibrillation with rapid ventricular response. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Cyclophosphamide/doxorubicin/trastuzumab

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Download PDF
1 page

Cyclophosphamide/doxorubicin/trastuzumab

Abstract

Reactions 1704, p124 - 2 Jun 2018 Cyclophosphamide/doxorubicin/ trastuzumab Irreversible left atrium dilatation, left ventricular dysfunction and atrial fibrillation with rapid ventricular response: case report A woman [exact age at the time of reaction onset not clearly stated] developed irreversible left atrium dilatation, atrial fibrillation with rapid ventricular response and left ventricular dysfunction following treatment with trastuzumab, cyclophosphamide and doxorubicin [dosages and...
Loading next page...
1
 
/lp/springer_journal/cyclophosphamide-doxorubicin-trastuzumab-6i9yTxgLKP

References (1)

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-018-46767-4
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p124 - 2 Jun 2018 Cyclophosphamide/doxorubicin/ trastuzumab Irreversible left atrium dilatation, left ventricular dysfunction and atrial fibrillation with rapid ventricular response: case report A woman [exact age at the time of reaction onset not clearly stated] developed irreversible left atrium dilatation, atrial fibrillation with rapid ventricular response and left ventricular dysfunction following treatment with trastuzumab, cyclophosphamide and doxorubicin [dosages and routes not stated; not all durations of treatments to reactions onsets and outcomes stated]. The woman was diagnosed with stage IV invasive ductal left breast cancer in 2002 (at the age of 52 years) with bone metastases. Following left-modified radical mastectomy, she received treatment with six cycles of doxorubicin followed by adjuvant CMF regimen that consisted cyclophosphamide, concurrently with methotrexate and fluorouracil. In November 2008, due to disease progression, she received treatment with trastuzumab plus docetaxel combination therapy. No heart disease was observed at baseline. However, after 22 months of trastuzumab initiation, the left atrial volume index (LAVI) was found to be increased, but the left ventricular function was preserved. She presented with the symptoms of fatigue, palpitation and exertional dyspnoea after six months. Electrocardiography findings led to the diagnosis of atrial fibrillation with rapid ventricular response.

Journal

Reactions Weekly – Springer Journals

Published: Jun 2, 2018

There are no references for this article.